Literature DB >> 17574982

(18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease.

Lisa Mosconi1, Wai Hon Tsui, Alberto Pupi, Susan De Santi, Alexander Drzezga, Satoshi Minoshima, Mony J de Leon.   

Abstract

UNLABELLED: The normative reference sample is crucial for the diagnosis of Alzheimer's disease (AD) with automated (18)F-FDG PET analysis. We tested whether an (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals ("normals," or NLs) would improve diagnosis of AD and mild cognitive impairment (MCI).
METHODS: Two (18)F-FDG PET databases of 55 NLs with 4-y clinical follow-up examinations were created: one of NLs who remained NL, and the other including a fraction of NLs who declined to MCI at follow-up. Each (18)F-FDG PET scan of 19 NLs, 37 MCI patients, and 33 AD patients was z scored using automated voxel-based comparison to both databases and examined for AD-related abnormalities.
RESULTS: Our database of longitudinally confirmed NLs yielded 1.4- to 2-fold higher z scores than did the mixed database in detecting (18)F-FDG PET abnormalities in both the MCI and the AD groups. (18)F-FDG PET diagnosis using the longitudinal NL database identified 100% NLs, 100% MCI patients, and 100% AD patients, which was significantly more accurate for MCI patients than with the mixed database (100% NLs, 68% MCI patients, and 94% AD patients identified).
CONCLUSION: Our longitudinally confirmed NL database constitutes reliable (18)F-FDG PET normative values for MCI and AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574982     DOI: 10.2967/jnumed.107.040675

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  25 in total

1.  Fluorodeoxyglucose positron emission tomography of mild cognitive impairment with clinical follow-up at 3 years.

Authors:  José V Pardo; Joel T Lee; Michael A Kuskowski; Kristin R Munch; John V Carlis; Sohail A Sheikh; Christa Surerus; Scott M Lewis; J Riley McCarten; Howard Fink; Susan McPherson; Hemant H Shah; Susan Rottunda; Maurice W Dysken
Journal:  Alzheimers Dement       Date:  2010-05-06       Impact factor: 21.566

Review 2.  Clinical utility of FDG-PET for the clinical diagnosis in MCI.

Authors:  Javier Arbizu; Cristina Festari; Daniele Altomare; Zuzana Walker; Femke Bouwman; Jasmine Rivolta; Stefania Orini; Henryk Barthel; Federica Agosta; Alexander Drzezga; Peter Nestor; Marina Boccardi; Giovanni Battista Frisoni; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-27       Impact factor: 9.236

Review 3.  Biomarkers for Alzheimer's disease: ready for the next step.

Authors:  Paul B Rosenberg; Argye E Hillis
Journal:  Brain       Date:  2009-07-16       Impact factor: 13.501

Review 4.  Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Authors:  Kaj Blennow; Bruno Dubois; Anne M Fagan; Piotr Lewczuk; Mony J de Leon; Harald Hampel
Journal:  Alzheimers Dement       Date:  2014-05-03       Impact factor: 21.566

Review 5.  Energy metabolism and inflammation in brain aging and Alzheimer's disease.

Authors:  Fei Yin; Harsh Sancheti; Ishan Patil; Enrique Cadenas
Journal:  Free Radic Biol Med       Date:  2016-05-03       Impact factor: 7.376

6.  FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.

Authors:  Lisa Mosconi; Rachel Mistur; Remigiusz Switalski; Wai Hon Tsui; Lidia Glodzik; Yi Li; Elizabeth Pirraglia; Susan De Santi; Barry Reisberg; Thomas Wisniewski; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-14       Impact factor: 9.236

7.  Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI).

Authors:  C Haense; K Herholz; W J Jagust; W D Heiss
Journal:  Dement Geriatr Cogn Disord       Date:  2009-09-25       Impact factor: 2.959

8.  Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.

Authors:  Lisa Mosconi; Wai H Tsui; Karl Herholz; Alberto Pupi; Alexander Drzezga; Giovanni Lucignani; Eric M Reiman; Vjera Holthoff; Elke Kalbe; Sandro Sorbi; Janine Diehl-Schmid; Robert Perneczky; Francesca Clerici; Richard Caselli; Bettina Beuthien-Baumann; Alexander Kurz; Satoshi Minoshima; Mony J de Leon
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

9.  Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly.

Authors:  Liana G Apostolova; Paul M Thompson; Steve A Rogers; Ivo D Dinov; Charleen Zoumalan; Calen A Steiner; Erin Siu; Amity E Green; Gary W Small; Arthur W Toga; Jeffrey L Cummings; Michael E Phelps; Daniel H Silverman
Journal:  Mol Imaging Biol       Date:  2009-07-28       Impact factor: 3.488

10.  Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Jessica B S Langbaum; Kewei Chen; Wendy Lee; Cole Reschke; Dan Bandy; Adam S Fleisher; Gene E Alexander; Norman L Foster; Michael W Weiner; Robert A Koeppe; William J Jagust; Eric M Reiman
Journal:  Neuroimage       Date:  2009-01-21       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.